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Introduction
Transforming growth factor (TGF)-β is a dimeric protein of
25kDa molecular weight, originally isolated from platelets
[1,2]. There are three distinct mammalian isoforms, TGF-β1,
TGF-β2 and TGF-β3, with TGF-β1 being the most abundant
isoform. Almost all cell types express TGF-β, but the highest
level of expression of TGF-β is in platelets and bone [3].
Mature TGF-β1 consists of two identical peptide chains,
each containing 112 amino acids, linked via nine disulfide
bonds [4]. TGF-β1 is synthesized as part of a large, latent
protein complex, unable to bind to cellular receptors, with
mature active TGF-β1 produced by cleavage [5].
TGF-β1 is a mutifunctional cytokine that plays an important
role in immunomodulation, inflammation and tissue repair
[6]. Many studies have suggested that TGF-β could be a
potential therapeutic reagent for the repair of soft tissue and
bone, and following ischemic injury. It may also have appli-
cations for the treatment of chronic inflammatory fibrotic and
autoimmune diseases [7,8]. In contrast, other studies have
demonstrated that TGF-β1 can cause inflammation and
fibrosis [9,10]. The potential use of TGF-β1 for the treat-
ment of human disease thus remains controversial [11].
Rheumatoid arthritis is a systemic, autoimmune disease. It
is characterized by a chronic, erosive inflammation of
painful and debilitating joints, with progressive degrada-
tion of cartilage and bone accompanied by proliferation of
the synovium [12]. Rheumatoid arthritis remains incurable
and, in many patients, difficult to treat. As a novel
Ad.Luc = adenoviral vector expressing luciferase; Ad.TGF = adenoviral vector expressing human transforming growth factor; AIA = antigen-induced
arthritis; ELISA = enzyme-linked immunosorbent assay; GAG = glycosaminoglycan; H & E = hematoxylin and eosin; IL = interleukin; TGF = trans-
forming growth factor.
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Abstract
To examine the effect of transforming growth factor (TGF)-β1
on the regulation of cartilage synthesis and other articular
pathologies, we used adenovirus-mediated intra-articular gene
transfer of TGF-β1 to both naïve and arthritic rabbit knee joints.
Increasing doses of adenoviral vector expressing TGF-β1 were
injected into normal and antigen-induced arthritis rabbit knee
joints through the patellar tendon, with the same doses of an
adenoviral vector expressing luciferase injected into the
contralateral knees as the control. Intra-articular injection of
adenoviral vector expressing TGF-β1 into the rabbit knee
resulted in dose-dependent TGF-β1 expression in the synovial
fluid. Intra-articular TGF-β1 expression in both naïve and
arthritic rabbit knee joints resulted in significant pathological
changes in the rabbit knee as well as in adjacent muscle tissue.
The observed changes induced by elevated TGF-β1 included
inhibition of white blood cell infiltration, stimulation of
glycosaminoglycan release and nitric oxide production, and
induction of fibrogenesis and muscle edema. In addition,
induction of chondrogenesis within the synovial lining was
observed. These results suggest that even though TGF-β1 may
have anti-inflammatory properties, it is unable to stimulate
repair of damaged cartilage, even stimulating cartilage
degradation. Gene transfer of TGF-β1 to the synovium is thus
not suitable for treating intra-articular pathologies.
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approach to therapy, we and other workers have focused
on developing the methods for local transfer of genes
encoding therapeutic agents to the joint [13–19]. This
strategy also can be applied to the treatment of
osteoarthritis and for aiding the repair of the cartilage and
other intra-articular tissues.
Since TGF-β1 has anti-inflammatory properties as well as
being able to stimulate new matrix synthesis by chondro-
cytes, it represents a possible therapeutic agent with
which to treat pathologies associated with rheumatoid
arthritis and osteoarthritis by local gene delivery. Other
workers and ourselves have previously examined the
effects of TGF-β1 gene transfer on matrix synthesis in
chondrocyte cultures, demonstrating a significant stimula-
tion in the production of proteoglycans [9]. In addition, we
have demonstrated that the TGF-β1 gene was able to
overcome the inhibitory effects of IL-1β on matrix metabo-
lism in chondrocytes in culture [20].
To examine the effect of TGF-β1 on joint pathology, we
used adenovirus-mediated intra-articular gene delivery to
confer sustained, intra-articular TGF-β1 expression in both
naïve and arthritic rabbit knee joints. Intra-articular injec-
tion of adenoviral vector expressing human transforming
growth factor (Ad.TGF)-β1 resulted in a high level of
TGF-β1 accumulation in the synovial fluid. Intra-articular
TGF-β1 expression was anti-inflammatory, inhibiting white
blood cells. However, TGF-β1 expression also induced
significant pathology in the rabbit knee as well as in the
adjacent muscle, including stimulation of glycosaminogly-
can (GAG) release and nitric oxide synthesis, and
enhancement of fibrogenesis and muscle edema. These
results suggest that, although TGF-β1 may have anti-
inflammatory effects, sustained expression of TGF-β1 has
adverse effects on joint pathology.
Materials and methods
Vector construction
The recombinant adenoviral vector used in the present
study originates from replication-deficient type 5 adeno-
virus lacking E1 and E3 loci [21]. The human TGF-β1
cDNA was inserted in place of the E1 region in the shuttle
plasmid pAd-Lox [22], where expression is driven by the
cytomegalovirus promoter.
The recombinant Ad.TGF-β1 virus was generated by Cre-
Lox-driven recombination in Cre 8 cells [22]. Briefly, a
confluent 10cm2 dish of Cre 8 cells (1.6×107) was split
into five 6cm2 dishes. Transfection of these cells with
pAd-Lox-human TGF-β1 was performed by the calcium
phosphate precipitation method with 3µg pAd-Lox-human
TGF-β1 construct digested with SfiI and 3µg ψ5 helper
virus DNA. The transfected Cre 8 cells were fed daily until
there were visible plaques. The cells were harvested and
exposed to three cycles of freeze/thaw. The recombinant
virus was purified and amplified by infecting two 10 cm
dishes of Cre 8 cells using 100µl lysate. The Ad.TGF-β1
virus was purified using cesium chloride gradient ultracen-
trifugation at 154,000g (30,000 rpm) and 4°C, and then
dialyzed three times against Tris-buffered saline.
The titer was determined by measuring the viral DNA at
optical density 260nm (OD260 nm) using the formula: viral
particles = OD260 nm×dilution / 9.09×10–13. The aden-
ovirus expressing luciferase was kindly provided by J Kolls
(LSU Medical Center, New Orleans, LA, USA).
Animals and experimental arthritis
New Zealand white rabbits, weighing 4–5kg, were pur-
chased from Myrtles Rabbitry (Thompson Station, TN,
USA). To establish antigen-induced arthritis (AIA), rabbits
were sensitized to ovalbumin by intradermal injections of 5
mg ovalbumin emulsified in Freund’s complete adjuvant.
Arthritis was initiated in both hind knees of rabbits 3
weeks later by the intra-articular injection of 5mg ovalbu-
min dissolved in 0.5ml Gey’s saline. The different adenovi-
ral vectors were injected intra-articularly 24 hours after
injection of antigen.
Experimental protocol
Twenty-four hours after induction of AIA, adenoviral parti-
cles encoding either the human TGF-β1 or luciferase were
suspended in 0.2ml Gey’s saline and injected into the
joint space of the knee through the patellar tendon. Differ-
ent doses of virus (1×107, 1×10 8 and 1×109) viral
particles were injected intra-articularly into three rabbits
per group for analysis of the effects of TGF-β1 on naïve
joint pathology, and the treated rabbits were sacrificed
7 days postinfection to observe the dose–response
effects. Another group of three naïve rabbits was injected
with 1×109 viral particles and sacrificed 17 days post-
infection for long-term observation.
There were two groups of AIA rabbits used in the study.
The first group of three rabbits was injected with 1×108
viral particles, and the second group of six rabbits was
injected with 1×109 viral particles. Each rabbit received
the indicated dose of TGF-β1 virus in one knee and the
same amount of the adenoviral vector expressing luciferase
(Ad.Luc) virus in the opposite knee as the control.
To lavage the rabbit knee joints, 1ml Gey’s saline was
injected into the joint space through the patellar tendon.
After manipulation of the joint, the needle was reinserted
and the fluid was aspirated. Leukocytes in recovered
lavage fluids were counted using a hemocytometer. The
levels of TGF-β1 in conditioned media, lavage fluids and
sera were measured using an ELISA kit (R&D Systems,
Minneapolis, MN, USA) as directed by the supplier. The
levels of sulfated GAGs in lavage fluids were determined
using a colorimetric dye-binding assay using 1,9-dimethyl-Arthritis Research & Therapy    Vol 5 No 3 Mi et al.
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methylene blue [23]. The levels of total nitrite in lavage
fluids were measured with Nitric Oxide Assay kits (Cal-
biochem®; Biosciences Inc, La Jolla, CA, USA).
Articular cartilage fragments shaved from the femoral
condyles were placed into 1ml Neuman–Tyell serum-free
medium (Gibco, New York, USA) to measure the rate of
proteoglycan synthesis. The fragments were then incu-
bated with 35SO4
2– (20µCi) for 24 hours at 37°C, and the
media harvested and stored at –20°C. Proteoglycans
were extracted from the cartilage by incubation for
48 hours in 1ml of 0.5M NaOH at 4°C with gentle agita-
tion. Following chromatographic separation of unincorpo-
rated 35SO4
2– using PD-10 columns (Pharmacia, Uppsala,
Sweden), the levels of radiolabeled GAGs released onto
the culture media or recovered by alkaline extraction were
quantitated by scintillation counting [24].
Histology
For histological analyses, tissues harvested from dis-
sected knees were first fixed in 10% formalin. The fixed
tissues were imbedded in paraffin, sectioned at 5µm, and
stained with H&E.
Statistical analysis
All data collected are expressed as mean±standard error.
Statistical significance was analyzed by analysis of vari-
ance and Student’s t test. Correlation coefficients (r) were
calculated using Pearson’s method.
Results
Expression of TGF-β β1 after intra-articular injection of
Ad.TGF-β β1
To test the effects of adenoviral-mediated human TGF-β1
gene expression in naïve and AIA rabbit joints, 1×107,
1×10 8 and 1×109 particles of Ad.TGF-β1 were injected
into either naïve or arthritic rabbit knees. The same
amounts of Ad.Luc were injected into the contralateral
knees. Lavages were performed on day 3, day 7 and
day 17, and the levels of TGF-β1 were determined by
ELISA (Fig.1).
TGF-β1 expression was detected in all knee joints receiv-
ing either 1×108 or 1×109 viral particles, with higher
levels detected in the arthritic knees. A significant drop in
TGF-β1 expression was observed after 17 days of post-
viral injection. No significant levels of TGF-β1 were
detected in the 1×107 viral particle injection group and in
the contralateral joints receiving the different doses of
luciferase virus. Furthermore, no significant expression of
TGF-β was detected in the serum.
It is important to note that detection of TGF-β1 in the syn-
ovial fluid required acid activation, suggesting that the
protein is in its latent form. Moreover, there were no
observed therapeutic or adverse effects following intra-
articular injection of the low dose (1×107 particles) of
Ad.TGF-β1.
Alterations in joint anatomy after intra-articular
Ad.TGF-β β1 injection
Three days after injection of Ad.TGF-β1, the knees receiv-
ing the highest dose of virus became enlarged with a
reduction in joint movement. In addition, the muscles adja-
cent to the joints showed signs of swelling and reduced
movement. The animals were sacrificed on day 7 post-
injection, and the joints were analyzed. The size of the joints
and the adjacent muscles increased dramatically both in
naïve rabbits (1.5×contralateral knees, P<0.05) and in AIA
rabbits (1.25×contralateral knees, P<0.01) (Fig.2).
Figure 1
Adenovirus-mediated transforming growth factor (TGF)-β1 gene expression in naïve and antigen-induced arthritis (AIA) rabbit joints. (A) 1×10 7,
1×10 8 and 1×109 adenoviral particles encoding human TGF-β1 cDNA were injected into naïve rabbit left knees. (B) 1×10 9 viral particles were
injected into naïve rabbit left knees. (C) 1×10 8 and 1×109 viral particles were injected into AIA rabbit left knees. The same amounts of control
viral particles were injected into the contralateral knees. Levels of TGF-β1 are expressed in nanograms per milliliter of lavage fluid recovered from
knees 3, 7 and 17 days postinfection. All values are expressed as mean±standard error of the mean.The movement of joints was also severely limited, with the
Ad.Luc contralateral knees moving freely at 180° whereas
the knees treated with Ad.TGF-β1 virus could only move at
90–120°. The limitation to joint movement was not due to
the enlarged muscles since, when the muscles were cut
away, the limitation of movement was still observed. In
addition, when the joints were analyzed 17 days after viral
injection, at a time when the muscle size returned to
normal, the joint still could not move freely. The limitation to
joint movement could thus be due to possible synovial
hyperplasia or effects on ligaments or cartilage metabolism.
It is important to note that we did observe an increase in
creatine kinase levels in the serum that would suggest
muscle damage (data not shown). In contrast to the high-
dose TGF-β1 group, only a very mild effect was observed
on the gross joint structure in the group receiving 1×108
viruses and no changes were observed in the group
receiving 1×107 viruses.
Effect of TGF-β β1 on cartilage metabolism
To determine whether overexpression of TGF-β1 had
effects on cartilage metabolism in naïve and AIA rabbit
joints, GAG synthesis by articular cartilage and GAGs
released into synovial fluid as a result of proteoglycan
breakdown were measured. The rabbit joints receiving
Ad.TGF-β1 had significant higher levels of GAG release,
compared with the contralateral Ad.Luc joints, in lavage
fluids at day 3, day 7 and day 17 for the naïve rabbits and
at day 7 for the AIA rabbits (Fig.3A–C). GAG release
levels correlated linearly with the levels of TGF-β1 in
lavage fluids (r=0.937) in the naïve rabbits. In addition,
only the highest dose of Ad.TGF-β1 was able to stimulate
GAG synthesis in the naïve rabbit joints from day 7 and
day 17, but the stimulation was marginal. There was no
statistically significant difference between GAG synthesis
by the naïve rabbits with the two lower doses of viral injec-
tions and in the AIA rabbits (Fig.3D–F).
Taken together, these results suggest that intra-articular
expression of TGF-β1 stimulated cartilage matrix degrada-
tion while having only a minor effect on the promotion of
new matrix synthesis. This is in contrast to the results
observed on matrix synthesis in chondrocytes in culture,
where TGF-β1 was able to stimulate significant new matrix
synthesis as well as overcome the suppressive effects of
IL-1β on matrix metabolism [21,25].
Inhibition of white blood cell infiltration and elevation
of nitric oxide synthesis
To determine whether TGF-β1 expression could inhibit the
mild inflammation induced by intra-articular injection of
high doses of adenovirus or the severe inflammation
occurring in the AIA model, the levels of white blood
leukocytic infiltrate in the synovial lavage fluids were deter-
mined (Fig.4).
The joints of naïve rabbits receiving the highest dose of
Ad.TGF-β1 adenovirus had significantly lower levels of white
blood cell infiltration in lavage fluids at day 3, day 7 and
day 17. The white blood cell infiltration in the naïve joints
directly correlated with TGF-β1 expression levels in the
lavage fluids (r=0.954). In the AIA rabbit knee joints, there
was a reduction in the infiltration at day 3 and day 7 com-
pared with the contralateral control Ad.Luc joints, consistent
with TGF-β1 having an anti-inflammatory effect. Surprisingly,
TGF-β1 expression elevated nitrate levels in the joints receiv-
ing high-dose injections of TGF-β1 adenovirus at day 3,
day 7 and day 17 for naïve rabbits and at day 7 for the AIA
rabbits, compared with the control joints (Fig.4D–F). The
nitrate levels also directly correlated with the levels of
TGF-β1 in lavage fluids (r=0.945) for naïve rabbits.
Available online http://arthritis-research.com/content/5/3/R132
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Figure 2
Gross pathology caused by intra-articular injection of adenoviral vector expressing human transforming growth factor beta 1 (Ad.TGF-β1) virus. 
(A) The naïve rabbit left knee injected with a high dose of the TGF-β1 virus and the right knee injected with a high dose of the luciferase virus. 
(B) The naïve rabbit left knee with a low dose of the Ad.TGF-β1 virus and the right knee with a low dose of the luciferase virus. These images were
taken when the rabbits were sacrificed on day 7.These results suggested that TGF-β1 is indeed anti-
inflammatory in arthritic knees, but is able to induce pro-
duction of nitric oxide through an unknown mechanism.
Histological analysis of the intra-articular effects of
TGF-β β1
The naïve and AIA rabbit knee joints receiving Ad.TGF-β1
and Ad.Luc were also examined by histology. There was
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Figure 3
Glycosaminoglycan (GAG) release into lavage fluids and GAG synthesis by articular cartilage recovered from the rabbit knees injected with
adenoviral vector expressing human transforming growth factor beta 1 (Ad.TGF-β1) (Exp.) or the control adenoviruses (Con.). (A, D) Short-term
naïve rabbits. (B, E) Long-term naïve rabbits. (C, F) Antigen-induced arthritis rabbits. All values are expressed as the mean±standard error of the
mean. * P<0.05 and ** P<0.01, compared with contralateral knees.
Figure 4
White blood cell (WBC) infiltration and nitrate levels in lavage fluids recovered from the rabbit knees injected with adenoviral vector expressing
human transforming growth factor beta 1 (Ad.TGF-β1) or the control adenoviruses. (A, D) Short-term naïve rabbits. (B, E) Long-term naïve rabbits.
(C, F) Antigen-induced arthritis rabbits. All values are expressed as the mean±standard error of the mean. * P<0.05 and ** P<0.01, compared
with contralateral knees.significant fibroblast proliferation around the myofibers in
the naïve rabbits joint receiving Ad.TGF-β1. There was
also mild hyperplasia of the synovial lining, but without any
evidence of inflammatory cells being observed (Fig.5A,B).
There were some inflammatory cells in the contralateral
synovial lining, but no evidence of synovitis (Fig.5C,D).
The synovium from the TGF-β1 virus treated joints was
highly fibrotic 17 days after viral injection, with evidence of
osteometroplasia found in the synovium (Fig.5E,F) but
with no evidence of inflammation or angiogenesis (Fig.5F).
There was mild inflammation under the synovium in the
contralateral joints receiving Ad.Luc (Fig.5G,H). The syn-
ovium in the Ad.TGF-β1-treated AIA rabbits showed evi-
dence of hyperproliferation with mild inflammation
(Fig.5I,J), compared with the contralateral control joints
that had severe inflammation (Fig.5K,L). In the muscle
tissue adjacent to Ad.TGF-β1-treated joints, there was evi-
dence of both fibroblast and myofibroblast proliferation
between myofibers with intracellular edema, but there was
no evidence of inflammation or myonecrosis (Fig.5M,N). In
contrast, the muscle tissue from the contralateral controls
knees was normal (Fig.5O,P). There was also mild fibrob-
last proliferation and synovial inflammation in the 1×108
Ad.TGF-β group, but no significant histological changes
were observed in the 1×107 viral group.
These data taken together suggest that TGF-β1 is able to
stimulate fibrogenesis and to suppress inflammation.
Moreover, the results suggest that elevated TGF-β1 levels
result in chondrogenesis within the synovial tissue.
Discussion
TGF-β1 is a mutifunctional cytokine that plays an impor-
tant role in immunomodulation, inflammation and tissue
repair. Given that TGF-β1 is able to induce new matrix
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Figure 5
Histological analyses of synovial tissue recovered from rabbit knees joints and muscular tissue adjacent to the joints. (A, B) Naïve rabbit left knees
were injected with 1×109 adenoviral vector expressing human transforming growth factor beta 1 (Ad.TGF-β1) viral particles. (C, D) The
contralateral knee joint of (A, B). (E, F) Long-term naïve rabbit left knees were injected with 1×109 Ad.TGF-β1 viral particles. (G, H) The
contralateral knee joint of (E, F). (I, J) Antigen-induced arthritis rabbit knees were injected with 1×109 Ad.TGF-β1 viral particles. (K, L) The
contralateral knee of (I, J). (M, N) Muscle from an adjacent naïve rabbit knee with 1×109 Ad.TGF-β1 viral particles. (O, P) The contralateral knee of
(M, N). (B), (F), (J), and (N) High magnification (400×) images of (A), (E), (I), and (M) (100×), respectively. (D), (H), (L), and (P) High magnification
(400×) images of (C), (G), (K), and (O) (100×), respectively.synthesis from chondrocytes in culture as well as able to
block inflammation in vivo, it has been proposed that local
intra-articular gene transfer of TGF-β1 could be therapeutic
for the treatment of rheumatoid arthritis as well as
osteoarthritis. To examine the effects of TGF-β1 on joint
pathology, we used adenovirus-mediated intra-articular
gene delivery to confer sustained intra-articular TGF-β1
expression in both naïve and arthritic rabbit knee joints.
Intra-articular injection of Ad.TGF-β1 virus into the rabbit
knee resulted in dose-dependent elevated levels of expres-
sion of TGF-β1 in the synovial fluid, but not in the serum.
Intra-articular TGF-β1 expression resulted in dose-depen-
dent biological effects in the rabbit knee as well as in adja-
cent muscle. In particular, local intra-articular expression in
naïve joints stimulated cartilage breakdown, as measured
by synovial GAG levels, without enhancing new matrix
synthesis. In addition, TGF-β1 expression stimulated nitric
oxide production. Similarly, in arthritic joints where TGF-β1
expression inhibited white blood cell infiltration, it also
stimulated GAG release and nitric oxide production.
Although there was a reduction in inflammation in arthritic
joints, TGF-β1 expression induced fibrogenesis and
muscle edema. In addition, TGF-β1 expression in the ade-
novirally infected synovial lining also resulted in induction
of chondrogenesis in the synovium. Elevated TGF-β1
expression in the synovial fluid thus resulted in a variety of
adverse pathological changes.
A previous study examined the effect of Ad.TGF-β1 in the
knee joints of naïve C57/Bl/6 mice where gene transfer of
TGF-β1 to the mouse knee resulted in hyperplasia of the
synovium as well as in chondro-osteophyte formation at the
chondrosynovial junctions [10]. The present experiments
have shown similar effects on synovial proliferation, but also
have extended the murine studies to examine the effects of
TGF-β1 in both diseased knee joints and normal knee joints
in the rabbit. Similar to the previous report, we have
observed evidence for intra-synovial chondrogenesis as well
as osteometroplasia following TGF-β1 gene transfer.
Whether TGF-β1 directly or indirectly stimulates prolifera-
tion of synovium is unclear, but this pathology apparently is
mediated through an IL-1β-independent mechanism.
It has been speculated that intra-articular delivery of
TGF-β1 would result in enhanced synthesis of new matrix
[9]. Indeed, we have reported previously that the TGF-β1
gene is more effective than insulin-like growth factor
type 1 and bone morphogenetic protein type 2 genes in
stimulating new matrix synthesis from rabbit chondrocytes
in culture. We have also demonstrated that TGF-β1 is able
to partially overcome the inhibition of new matrix synthesis
by IL-1β in cultured chondrocytes. The results presented
in the present article, however, suggest that TGF-β1
expression is unable to enhance new matrix synthesis
in vivo in either naïve joints or, in particular, in diseased
joints. Moreover, it appears as if TGF-β1 confers adverse
effects by stimulating cartilage degradation through an
unknown mechanism. In contrast to the adverse effects of
intra-articular adenoviral gene transfer of TGF-β1, we have
shown that gene transfer of insulin-like growth factor
type 1 to the rabbit knee results in an increase in new
matrix synthesis without any adverse effects [17].
Taken together, these results suggest that increasing the
intra-articular levels of TGF-β1 has no therapeutic effect
on cartilage metabolism, resulting instead in higher rates
in cartilage degradation. Use of the synovium as a target
tissue for TGF-β1 gene transfer, resulting in elevating the
intra-articular level, is thus not appropriate for the
enhancement of repair of cartilage defects. Instead, for
TGF-β1 gene therapy to be effective in promoting repair of
damaged cartilage, the level of TGF-β1 will need to be
highly regulated as well as expression localized. TGF-β1
expression would need to be targeted, at the appropriate
levels, to the site of cartilage damage, such as through
gene transfer to chondrocytes or stem cells involved in
repairing the damaged tissues.
TGF-β1 has been shown to be therapeutic in several dif-
ferent animal models when expressed systemically from
muscle tissue [26,27]. This suggests that elevated serum
levels of TGF-β1 can reduce general inflammation as well
as inhibit IL-1β and tumor necrosis factor alpha produc-
tion, resulting in a systemic therapeutic effect. In addition,
TGF-β1 has been shown to be therapeutic in murine
models of collagen-induced arthritis following delivery in
genetically modified T cells [28]. This observation sug-
gests that targeting TGF-β1 to certain sites of inflamma-
tion through the use of arthogenic T cells also can be
therapeutic. However, our results suggest that local
expression of TGF-β1, unlike systemic expression, is not
therapeutic due to adverse pathologies associated with
elevated intra-articular TGF-β1 expression.
Although our results do not preclude the development of
gene therapy approaches to express regulated TGF-β1
systemically to downmodulate the immune response, the
results suggest that any clinical application of local
TGF-β1 gene transfer should proceed with caution.
TGF-β1 is clearly a potent cytokine, able to confer multiple
effects when expressed intra-articularly in vivo.
Conclusion
Gene transfer represents a novel method for obtaining
high intra-articular levels of therapeutic agents for the
treatment of arthritis. TGF-β1 is able to stimulate new
matrix synthesis by chondrocytes in culture as well as able
to reduce inflammation in vivo. In this report, the effects of
intra-articular expression on both naïve and arthritic rabbit
knee joint pathology were examined by adenoviral-medi-
ated intra-articular gene transfer of TGF-β1. The results
Arthritis Research & Therapy    Vol 5 No 3 Mi et al.
R138suggest that elevated TGF-β1 expression confers adverse
joint pathology including an increase in cartilage matrix
degradation without stimulating new matrix synthesis. In
addition, TGF-β expression induces muscle edema and
fibrogenesis.
Although TGF-β1 may have certain anti-inflammatory prop-
erties, it is unable to stimulate repair of damaged cartilage,
and even stimulates cartilage degradation. Moreover, ele-
vated TGF-β1 expression also induced muscle edema and
fibrogenesis. Gene transfer of TGF-β1 to the synovium is
thus not suitable for treating intra-articular pathologies,
such as the repair of damaged cartilage, associated with
rheumatoid arthritis and osteoarthritis.
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